Answers are grounded in this paper and cite their sources.
Daratumumab, lenalidomide and dexamethasone (DRd) is a standard first-line treatment for transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM). We retrospectively evaluated 268 patients treated with DRd at nine Japanese institutions. The overall and complete response rates were 90.6% and 28.9%, respectively. At a median follow-up of 22.2 months, 2-year progression-free survival (PFS) and overall survival were 74.6% and 86.2%. PFS in patients with t(11;14) tended to be shorter than that in those without t(11;14) (hazard ratio [HR], 1.483; p = 0.139). Two-year PFS differed across R2-ISS stages I–IV (94.1%, 82.2%, 74.6%, and 68.1%; log-rank p = 0.002). Among 208 patients with complete six-group cytogenetic classification, t(11;14) with del(17p) and/or 1q21 abnormalities (n = 16) was associated with shorter PFS than the reference cytogenetic group in an exploratory comparison (HR, 2.470; p = 0.042). These findings indicate that coexisting cytogenetic abnormalities may modify the prognostic implications of t(11;14) with numerical cytogenetic abnormalities, requiring validation in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: